140 results about "Acetylglucosamine" patented technology

The invention relates to a construction method of escherichia coli engineering bacteria with high yield of N-acetylglucosamine. According to the method, the metabolic network of escherichia coli is directionally modified through metabolic engineering, the problems of'product re-decomposition ', by-product accumulation, poor genetic stability and the like of natural strains are solved, and efficient industrial production of GlcNAc is realized.

This invention provides a composition for improving bone and joint health, its preparation method, and its application, relating to the field of bone and joint health products technology. By weight, the composition for improving bone and joint health comprises the following components: 0.5-5 parts collagen peptides, 5-30 parts mangosteen extract, 0.5-3 parts non-denatured type II collagen peptides, 0.1-2 parts milk mineral salts, 0.3-3 parts bone collagen peptides, 0.1-2 parts cartilage extract, 0.1-2 parts N-acetylglucosamine, 0.1-2 parts sodium hyaluronate, and 0.3-3 parts turmeric extract. This invention, through multiple combinations of mangosteen extract and turmeric extract, and cartilage extract and sodium hyaluronate, obtains a composition that is low in cost, highly safe, and has a good effect on the prevention or improvement of bone and joint diseases.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention discloses recombinant escherichia coli with high yield of N-acetylneuraminic acid and application of the recombinant escherichia coli, and relates to the technical field of biological genetic engineering. The invention relates to a recombinant escherichia coli, which is characterized in that the escherichia coli is taken as a host, and free expression of an N-acetylmannosamine epimerase gene yihS from Streptomyces xiamenensis or an N-acetylmannosamine epimerase gene ce3 from Bacteroides polymorpha and an exogenous N-acetylneuraminic acid lyase gene nano A is carried out; and carrying out recombinant expression on N-acetyl hexosamine 1-kinase nahK, a UDP-N-acetyl glucosamine pyrophosphorylase gene glmU and a UDP-N-acetyl glucosamine-2-epimerase gene neuC in the other synthetic route of the ManNAc. According to the recombinant escherichia coli with high yield of N-acetylneuraminic acid, the yield of N-acetylneuraminic acid can reach 23.08 g / L under a shake flask fermentation condition; a two-stage batch feeding strategy is adopted, the yield of N-acetylneuraminic acid in a 5L fermentation tank reaches 71.25 g / L, the molar conversion rate of GlcNAc reaches up to 57.60%, and the method has the potential of industrial application.

The invention discloses an engineered glycosyl transferase and application thereof in efficient preparation of triterpenoid saponin. The engineered glycosyl transferase is obtained by mutating serine at the 15th site of UGT74AC1 enzyme into alanine, mutating histidine at the 47th site into aspartic acid, mutating leucine at the 48th site into valine, mutating alanine at the 180th site into serine, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid The mutant is obtained by mutating serine at the 332 site into proline, phenylalanine at the 367 site into tryptophan and lysine at the 420 site into arginine. According to the invention, the glycosyl transferase with high catalytic activity is obtained by modifying an enzyme engineering technology, and good application of the glycosyl transferase in synthesis of triterpenoid saponin is realized. The glycosyl transferase disclosed by the invention can also be coupled with sucrose synthase, or coupled with N-acetylhexosamine kinase and N-acetylglucosamine-1-uridine phosphate transferase, and acetylglucosamine is used as a glycosyl donor, so that cascade production of triterpenoid saponin with lower cost and higher efficiency is realized.

The invention provides a nutrition enhancer beneficial to bone health of middle-aged and elderly people, a preparation method of the nutrition enhancer and application of the nutrition enhancer in preparation of medial care food, and belongs to the field of nutritious food. The nutrient supplement comprises a plant fermentation product, osteopontin peptide, collagen peptide, N-acetylglucosamine and calcium, vitamins and mineral substances can be added, and the plant fermentation product is obtained by performing anaerobic fermentation on rhizoma drynariae and chestnuts through a complex microbial inoculant composed of lactobacillus reuteri and bifidobacterium longum subsp. Longum; the collagen peptide is prepared by performing enzymolysis on bovine bones through alkaline protease and flavourzyme; the hydrogel is prepared by adopting a sodium alginate-calcium chloride-carboxymethyl chitosan micro-capsule embedding process. An in-vitro experiment shows that the nutrition enhancer can remarkably promote osteoblast proliferation, differentiation and mineralization; animal experiments show that the bone mineral density of osteoporosis model mice can be effectively improved. The nutrition enhancer disclosed by the invention is suitable for preparing care food and bone health products, and has a remarkable effect of improving bone health of middle-aged and elderly people.

The invention discloses an N-acetylglucosamine transferase AcetRS-K23G and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the N-acetylglucosamine transferase AcetRS-K23G is as shown in SEQ ID NO. 3. The invention further discloses an application of the N-acetylglucosamine transferase AcetRS-K23G in the preparation of the chitosan oligosaccharide. The N-acetylglucosamine transferase AcetRS-K23G disclosed by the invention is obtained by performing mutation modification on the N-acetylglucosamine transferase AcetRS, and can be used for producing the chitosan oligosaccharide with the polymerization degree of 5-7, especially the heptaose, the yield of the heptaose can reach 42.01 mg / L, and the N-acetylglucosamine transferase AcetRS-K23G is an ideal functional enzyme for industrially producing the heptaose. The product spectrum of the N-acetylglucosamine transferase is widened, and the N-acetylglucosamine transferase can be used for preparing high-polymerization-degree chitosan oligosaccharide and has a wide application prospect.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

The invention relates to the fields of enzyme engineering and microbial fermentation production, in particular to an N-acetylglutamate synthetase mutant for producing N-acetyl blue and application of the N-acetylglutamate synthetase mutant. According to the invention, the N-acetylglutamate synthetase mutant EcargAV323A / S435A is constructed by researching the structure of N-acetylglutamate synthetase ArgA (EcargA) from Escherichia coli and mutating the 323rd site and the 435th site of EcargA protein in combination with a directed evolution technology, so that the N-acetylglutamate synthetase mutant EcargAV323A / S435A is constructed. When the engineering strain of the N-acetylglutamate synthetase mutant is used for producing the N-acetylobservation blue through fermentation, the yield of the N-acetylobservation blue can be remarkably improved, the generation of a by-product observation blue is reduced, the fermentation process is simplified, and the production cost is reduced. The N-acetylglutamate synthetase mutant and the engineering strain provided by the invention have good industrial application value.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention discloses a nano vesicle with tissue targeting and mitochondrial localization as well as preparation and application of the nano vesicle. The nano-vesicle is a nucleus pulposus cell membrane entrapped with a small molecule mitochondrial membrane stabilizer, and tetra-acetylated N-acetamido mannose is added in the culture process of nucleus pulposus cells, so that a sialic acid derivative with an azide group is expressed on the surface of the nucleus pulposus cell membrane. Therefore, triphenylphosphine cations are modified on the surface of the nucleus pulposus cell membrane through a biological orthogonal reaction. The nano-vesicle can stabilize a mitochondrial membrane structure, improve cell aging-related secretion phenotype release and mitochondrial functions, block mtDNA release and SASP factor generation, realize anti-aging, anti-inflammatory and tissue degeneration intervention, can be used for preparing intervention drugs for tissue degeneration diseases related to mitochondrial membrane damage, and has broad application prospects. Or a drug for regulating mtDNA leakage and SASP release in a cell aging model. Wide application prospects and important clinical transformation values are realized.

The invention belongs to the technical field of biological enzyme engineering, and particularly relates to a glucosamine-6-phosphate synthetase mutant and application thereof. A plurality of glucosamine-6-phosphate synthase mutants capable of remarkably improving the yield of N-acetylglucosamine are screened by performing single-point mutation or combined mutation on amino acid residues near a substrate binding pocket of the glucosamine-6-phosphate synthase or on the surface of protein of the glucosamine-6-phosphate synthase. According to the technical scheme, a foundation is laid for producing glucosamine by further transforming escherichia coli through metabolic engineering.

The invention provides a method for treating autoimmune diseases mediated by regulatory T cell (Treg) programmed necrosis. Specifically, the invention provides application of an O-linked beta-N-acetylglucosamine glycosylation (O-GlcNAcylation) accelerant, and the O-linked beta-N-acetylglucosamine glycosylation accelerant is used for preparing a medicine or a preparation for treating programmed necrosis type autoimmune diseases. It is found for the first time that when the O-GlcNAcylation promoter is used for improving the O-GlcNAcylation level of RIPK1 / 3 protein, Treg programmed necrosis can be effectively inhibited, and therefore autoimmune diseases are improved.

The invention discloses a genetically engineered bacterium for producing heparinogen and a construction method and application thereof, the genetically engineered bacterium takes Escherichia coli Nissle 1917 as a chassis bacterium, and the construction method comprises the following steps: (1) knocking out endonuclease I coding gene endA in a chassis bacterium genome; (2) knocking out a 6-phosphofructokinase I coding gene pfkA in a chassis bacterium genome; (3) carrying out overexpression on a 6-phosphoglucosamine synthetase encoding gene glmS and / or a UDP-glucose-6-dehydrogenase encoding gene kfiD from a chassis bacterium genome; (4) removing the feedback inhibition of the 6-phosphate glucosamine on the GlmS so as to promote the synthesis of UDP-N-acetylglucosamine; and (5) knocking out the 6-phosphate glucosamine deaminase coding gene nagB in the chassis bacterium genome. The engineering strain obtained by the invention can more efficiently synthesize the proheparin, the shake flask titer reaches 397.9 mg / L, which is increased by about 3 times compared with a wild strain, and the engineering strain has certain industrial application value.

The present application belongs to the field of genetic engineering and microbial fermentation technology, and particularly relates to a recombinant Escherichia coli for producing N-acetylglucosamine as well as a construction method and application thereof. The present application takes Escherichia coli as a chassis, knocks out the nagDCABE gene cluster, the manXYZ gene cluster and the serA gene of the genome of the Escherichia coli, and introduces the glmS, GNA1 and serA genes into the Escherichia coli through a vector for expression. The yield of the Escherichia coli for fermenting GlcNAc provided by the present application can reach more than 100 g / L.

The present application relates to a kind of targeting bacterial UDP-N-acetylglucosamine enolpyruvate transaminase antibacterial compound and its application, the antibacterial compound is S-(4-chlorobenzyl) chloro isothiourea, its chemical structure is as shown in formula I: I;Or its pharmaceutically acceptable salt, stereoisomer, solvate, crystal form, isotopically labeled or prodrug.The antibacterial compound of the present application can effectively inhibit the growth of klebsiella pneumoniae, including carbapenem-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae;It also has good bacteriostatic effect on escherichia coli and pseudomonas aeruginosa;It is expected to be applied to the clinical treatment of infection caused by drug-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae and other pathogenic bacteria, and has important clinical significance and social benefits.

The invention discloses a method for producing oligosaccharide by cooperatively treating aspergillus niger residues through multiple enzymes. The method comprises the following steps: mixing pretreated aspergillus niger residues with hydrochloric acid, carrying out acidolysis wall breaking, and carrying out suction filtration on an obtained wall-broken mixture; carrying out mixed treatment on filtrate obtained by suction filtration with cellulase and beta-glucanase, filtering, and carrying out concentration and alcohol precipitation on supernate to obtain soluble beta-glucan oligosaccharide; performing filter residue enzymolysis on filter residues obtained by suction filtration by using mesoporous silica immobilized chitinase, and recovering the immobilized chitinase after enzymolysis; and filtering the mixed solution subjected to enzymolysis by using the immobilized chitinase, and carrying out alcohol precipitation on the supernate to obtain the N-acetylglucosamine and the chitosan oligosaccharide. According to the method disclosed by the invention, the aspergillus niger residues are jointly treated by adopting multiple enzymes, the yield of N-acetylglucosamine and chitosan oligosaccharide reaches 85.1%-88.5%, and the yield of beta-glucosamine oligosaccharide reaches 86.7%-89.3%. The invention provides a brand new route for producing various oligosaccharides by utilizing solid waste aspergillus niger residues in the fermentation industry.

The present invention provides a copolymer which has a hydrophobic constituent unit (a), wherein the polymer terminal is a structure (T) containing a trithiocarbonate structure and a C8-15 hydrocarbon group. The present invention also provides a copolymer which has a constituent unit (b) containing an N-acetylglucosamine group, wherein the polymer terminal is a structure (T) containing a trithiocarbonate structure and a C8-15 hydrocarbon group.

A method for producing modified cells lacking mannosyl(alpha-1,3)-glycoprotein beta-1,2-N-acetylglucosamine transferase 1 ("MGAT1") activity is provided. The MGAT1 activity-deficient CHO cell line produced by this method is also provided. A method for producing glycoproteins is further disclosed.

The invention provides a composition containing pyrroloquinoline quinone or salt thereof and N-acetylglucosamine and application of the composition, the mass ratio of pyrroloquinoline quinone or salt thereof to N-acetylglucosamine is 0.1: (0.5-6), preferably 0.1: (1-5), pyrroloquinoline quinone or salt thereof and N-acetylglucosamine in the composition are compounded, and the composition has the advantages that the composition can be used for preparing the compound, and the compound can be used for preparing the compound. The composition can achieve a synergistic effect and is used for moisturizing or cartilage repair.

The application discloses a purification method of plant exosome, and belongs to the technical field of biological separation. The method comprises the following steps: obtaining plant juice or tissue extract, pre-treating the plant juice or tissue extract through coarse filtration and centrifugation, incubating the plant juice or tissue extract with magnetic microspheres modified with carboxyl or epoxy groups in a buffer containing calcium ions, capturing the complex by using an external magnetic field, washing the complex, eluting the complex by using a competitive elution buffer containing N-acetylglucosamine, and further purifying the complex by using a size exclusion chromatography column to obtain the plant exosome. The exosome is specifically captured by the magnetic microspheres, and the double purification strategies of competitive elution and size exclusion chromatography are combined, so that the recovery rate and purity of the exosome are significantly improved. The method is simple in operation, short in time consumption, good in repeatability, and suitable for the large-scale preparation of exosomes of various plant sources. The plant-derived exosome prepared by the method can be applied to the fields of drug delivery systems, cosmetics, respiratory health and sensory health product development.

The invention discloses an N-acetylglucosamine transferase AcetRS-R346T-K23V and an application thereof, and belongs to the technical field of functional enzymes. The amino acid sequence of the N-acetylglucosamine transferase AcetRS-R346T-K23V is as shown in SEQ ID NO.7. The invention also discloses the application of the N-acetylglucosamine transferase AcetRS-R346T-K23V in preparation of chitohexaose. The N-acetylglucosamine transferase AcetRS-R346T-K23V disclosed by the invention is extremely high in specificity of producing the chitohexaose, and the chitohexaose accounts for 93.21% in an enzymolysis product of the N-acetylglucosamine transferase AcetRS-R346T-K23V; moreover, the enzymolysis product only contains two kinds of chitosan oligosaccharides and does not contain chitotetraose and chitoheptaose, which is extremely beneficial to the subsequent efficient separation of chitohexaose. The N-acetylglucosamine transferase AcetRS-R346T-K23V disclosed by the invention can be used for efficiently producing the chitohexaose, and has a good application prospect.

The invention provides a drug carrier based on N-acetylglucosamine, a drug preparation and a preparation method. The drug carrier based on N-acetylglucosamine comprises N-acetylglucosamine and a cross-linking agent, the cross-linking agent is a compound with an aldehyde group or a ketone group, and the aldehyde group or the ketone group reacts with the deacetylated N-acetylglucosamine to generate one or more of a hydrazide bond, a hydrazone bond or an imine bond. The drug carrier based on N-acetylglucosamine shows remarkable advantages in the aspects of particle size distribution, drug loading capacity, encapsulation efficiency and cumulative drug release rate.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

The invention provides a composition for preventing or treating pet magnesium ammonium phosphate calculus and application thereof. The composition comprises a urine acidifying agent, a calculus formation inhibitor and a urinary tract repairing agent, the urine acidifying agent comprises any one or a combination of at least two of vitamin C, phosphate or methionine; the calculus formation inhibitor comprises a seaweed extract or / and chitosan oligosaccharide; the urinary tract repairing agent comprises any one or a combination of at least two of curcumin, hyaluronic acid, N-acetylglucosamine or cranberry extract. The composition provided by the invention synergistically maintains the pH value of pet urine to be weakly acidic, inhibits the generation of alkaline calculi, dissolves the formed alkaline calculi, repairs and protects urinary tract mucous membranes, realizes the nursing of the pet urinary system, and improves the health of the urinary system.

The invention relates to the technical field of functional food, in particular to an electrolyte composition beneficial to joint injury repair after exercise and a preparation method of the electrolyte composition. The electrolyte composition is mainly prepared from the following raw materials in parts by mass: 0.1 to 2 percent of N-acetylglucosamine, 0.05 to 0.5 percent of cartilage extract, 0.05 to 0.5 percent of enzymolysis bone meal, 0.01 to 0.05 percent of milk mineral salt, 0.1 to 1 percent of collagen peptide, 0.01 to 0.3 percent of vitamin and 0.03 to 0.3 percent of electrolyte. The nano hydrated milk mineral salt is adopted, the absorption efficiency of elements such as calcium and phosphorus in a body is improved, and the electrolyte composition is prepared by combining components such as N-acetylglucosamine and the cartilage extract, so that joint inflammation and cartilage injury caused by exercise are effectively improved while water and electrolyte are supplemented, and the activity of joints and exercises is improved. The electrolyte composition is good in taste, high in stability and suitable for joint protection and nutrition supplement after exercise.

The application belongs to the technical field of genetic engineering, and discloses a kind of synthetic lactosyl-N-neotetraose and safe recombinant bacillus subtilis and its construction method and application, the recombinant bacillus subtilis is obtained by transforming plasmid containing beta-1,3-N-acetylglucosamine transferase, beta-1,4-galactosyltransferase gene and lactose permease gene in bacillus subtilis 168.The application aims at the huge demand of lactosyl-N-neotetraose in the market in prior art, and the lactosyl-N-neotetraose produced by most existing engineering bacteria is not safe, provides an engineering bacteria for producing lactosyl-N-neotetraose and application, to meet the demand of lactosyl-N-tetraose in the market.

The invention discloses a method for purifying plant exosomes, which belongs to the technical field of biological separation and comprises the following steps: acquiring plant juice or tissue extracting solution, performing rough filtration and centrifugal pretreatment, incubating the plant juice or tissue extracting solution and magnetic microspheres of which the surfaces are modified with carboxyl groups or epoxy groups in a buffer solution containing calcium ions, capturing a compound by using an external magnetic field, and purifying the plant exosomes. After cleaning, eluting by adopting a competitive elution buffer solution containing N-acetylglucosamine, and finally further purifying by virtue of a size exclusion chromatographic column, so as to obtain the plant exosome. The exosome is specifically captured through the magnetic microspheres, the recovery rate and purity of the exosome are remarkably improved by combining a dual purification strategy of competitive elution and size exclusion chromatography, operation is easy and convenient, consumed time is short, repeatability is good, and the method is suitable for large-scale preparation of exosomes of various plant sources; the plant-derived exosome prepared by the method can be applied to the fields of product development of drug delivery systems, functional foods, cosmetics, respiratory health and sensory health and the like.

The invention relates to the technical field of microbial fermentation and enzyme engineering, and in particular relates to a strain Precottula equi GXAS 17-2 for high yield of chitin deacetylase as well as a fermentation culture medium and application thereof, the preservation number of the strain Precottula equi GXAS 17-2 is GDMCC NO: 67488, and the strain is separated from mangrove forest soil and can efficiently produce enzyme in the culture medium taking N-acetylglucosamine (GlcNAc) as an inducer. The enzyme activity is remarkably improved by optimizing culture medium components (3% of colloidal chitin, 10% of yeast powder and 0.3% of GlcNAc) and culture conditions (30 DEG C, 180 rpm, pH 7 and 48 h). The method has the advantages of high induction efficiency, green process, stable enzyme activity and the like, and is suitable for chitin degradation and chitosan green preparation industry.